

(¥ million)

	2014	2015	2016	2017	2018	2019	2020 (estimated)
Net Sales	79,991	84,209	98,781	101,448	114,716	116,637	123,000
Operating profit	8,562	8,549	15,280	17,079	20,644	21,668	25,000
Ordinary Profit	8,928	8,952	16,244	17,451	21,540	22,442	25,500
Profit attributable to owners of parent	5,882	6,340	11,749	12,953	16,302	16,866	19,000

(¥ million)

Brand name	Active Ingredient	Indications	Launch Date	Sales 2018	Sales 2019	Sales 2020	
						Apr.-Dec.	Annual (estimated)
Vidaza	azacitidine	myelodysplastic syndrome	Mar-11	14,453	15,652	11,884	16,000
Zalutia	tadalafil	urinary disorder caused by benign prostatic hyperplasia	Apr-14	12,118	13,328	5,685	7,000
Tramal, Onetram	tramadol hydrochloride	cancer pain, chronic pain	Sep-10	7,196	7,153	5,385	7,000
Uptravi	selexipag	pulmonary arterial hypertension	Nov-16	4,825	6,182	5,296	7,400
Adcirca	tadalafil	pulmonary arterial hypertension	Dec-09	5,173	5,405	4,274	5,600
Gazyva	obinutuzumab	CD20-positive follicular lymphoma	Aug-18	1,417	4,527	4,051	5,600
Cialis	tadalafil	erectile dysfunction	Jul-09	4,592	4,472	2,129	2,600
Defitelio	defibrotide sodium	sinusoidal obstruction syndrome	Sep-19	-	1,071	1,460	2,200
Azunol Gargle	sodium gualenate	pharyngitis, tonsillitis, stomatitis, etc.	Aug-02	2,169	2,159	1,333	1,900
Erizas	dexamethasone cipeclilate	allergic rhinitis	Dec-09	2,987	2,387	1,051	2,100
Profit in co-promotion				5,057	5,963	6,375	8,400
Revenues from the licensing of industrial				16,621	15,860	17,637	22,500
Pharmaceuticals				100,223	101,643	80,243	107,700
Functional Food				14,492	14,994	11,594	15,300
Net Sales				114,716	116,637	91,837	123,000